Skip to main content
Premium Trial:

Request an Annual Quote

Caprotec Raises $5M in Series B Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German protein reagents and sample prep technology firm Caprotec Bioanalytics said yesterday that it has closed on a €4 million ($5 million) Series B financing round.

Proceeds will be used to further develop its Capture Compound Mass Spectrometry technology for analyzing complex protein mixtures, the firm said in a statement. Specifically, Caprotec will continue development of its caproKits for the identification of functionally selected protein classes, as well as its ImproMed application for profiling drug interactions.

Participants in the financing included existing investors Creathor Venture, IBB Beteiligungsgesellshaft, ERP Startfonds, and private investors, the Berlin-based company said.

Caprotec's technology, called CCMS, is based on tri-functional molecules called capture compounds, and can be used to define and confirm drug targets and to discover off-target proteins that cause side effects.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.